ESMO Breast 2022 | ADAPT: de-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel in HR-/HER2+ eBC

Nadia Harbeck, MD, PhD, Ludwig Maximilians University – Grosshadern, Munich, Germany, discusses the survival results of the ADAPT (NCT01779206) study, reporting on the first data on the outcomes of a de-escalated neoadjuvant regimen of 12 weeks of trastuzumab plus pertuzumab with or without paclitaxel in patients with HER2-positive, HR-negative early breast cancer. A high pathologic complete response (pCR) of over 90% was observed with chemotherapy in patients who were low-intermediate risk. If patients have a de-escalated regimen and achieved a pCR, they may only require antibody treatment for the remainder of the year and no further chemotherapy, which is currently being explored in the Phase II Decrescendo (NCT04675827) trial in Europe and the Phase III CompassHER2 RD (NCT04457596) trial in the US. If patients do not achieve a pCR with maintenance in the adjuvant setting, then they may require escalated therapies. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.